Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 15

Explainer

CJC-1295 Side Effects in Human Trials

Early CJC-1295 trials reported no serious reactions, but lacked a full public event table and cannot establish long-term safety.

26 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Is CJC-1295 Prohibited by WADA?

CJC-1295 is named in WADA section S2.2.4 and is prohibited in and out of competition under the 2026 Prohibited List.

26 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GSD Ia and a Semaglutide Case Report

A 2026 case report shows why a rare glucose-storage disorder changed the semaglutide plan for one adolescent with obesity and liver lesions.

26 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Country deep-dive

Ipamorelin cost in Germany: the facts

No official German ipamorelin pharmacy price could be verified. Here is what the EU, reimbursement and vendor-price records show.

26 Oct 2026 · PeptideMethods Editorial Team · 6 min read
Explainer

Oral Semaglutide and CVR R

A small retrospective study linked lower deep breathing CVR R with early oral semaglutide discontinuation. It cannot predict an individual's tolerance.

26 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

How PT-141 works in the brain

PT-141 activates melanocortin receptors in the brain, but the full path from receptor binding to changes in sexual desire remains unknown.

26 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Retatrutide history: 2022 to today

Retatrutide moved from a 2022 discovery paper to Phase 3 obesity results in four years, but it remains investigational and unapproved.

26 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

How retatrutide works: three receptors

Retatrutide activates GIP, GLP-1 and glucagon receptors, combining appetite and glucose signals with a proposed energy-expenditure effect.

26 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Expert digest

Selank: Is There a Best Time of Day?

No human study establishes a best time of day for Selank or shows that morning, afternoon, or bedtime use changes sleep.

26 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Beyond LDL-C: Three Complex Cases

A 2026 case-based review shows how ApoB, particle measures, imaging and genetics can add context when LDL-C tells only part of the story.

25 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Expert digest

CJC-1295 No DAC and Visceral Fat

Human CJC-1295 studies did not test no-DAC material for visceral fat loss, so they cannot support a starting dose or cycle.

25 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Diabetes Drugs After 65: 2026 Review

A 2026 review weighs tirzepatide and other diabetes drugs for older adults against frailty, hypoglycaemia and treatment burden.

25 Oct 2026 · PeptideMethods Editorial Team · 5 min read